Silence Therapeutics plc (LON:SLN – Get Free Report) was down 0.9% on Thursday . The company traded as low as GBX 512 ($6.49) and last traded at GBX 535 ($6.78). Approximately 913,528 shares traded hands during mid-day trading, an increase of 1,040% from the average daily volume of 80,100 shares. The stock had previously closed at GBX 540 ($6.84).
Silence Therapeutics Trading Down 0.9 %
The company has a debt-to-equity ratio of 0.80, a current ratio of 4.52 and a quick ratio of 4.36. The company has a market capitalization of £480.35 million and a price-to-earnings ratio of -11.01. The business’s 50-day moving average price is GBX 535 and its two-hundred day moving average price is GBX 535.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Further Reading
- Five stocks we like better than Silence Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- The Most Important Warren Buffett Stock for Investors: His Own
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- What is Insider Trading? What You Can Learn from Insider Trading
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
